Vlad Coric

Vlad Coric, M.D. is the Chairman and Chief Executive Officer of Biohaven, a publicly traded biopharmaceutical company focused on discovering, developing, and commercializing life-changing therapies for neurological, neuropsychiatric, immunological, and oncology indications. As CEO, Dr. Coric has guided Biohaven’s transformation from an entrepreneurial start-up into a modern pharmaceutical leader with a bold scientific vision and a commitment to patients. He played a central role in advancing landmark FDA approvals for migraine treatments and in orchestrating the strategic acquisition of Biohaven’s CGRP portfolio by Pfizer, helping to create significant value for patients and shareholders alike.

Before leading Biohaven, Dr. Coric held senior research and leadership roles, including Group Director of Global Clinical Research at Bristol-Myers Squibb, and has more than 20 years of experience in drug discovery and clinical development across multiple therapeutic areas. He also serves as an Associate Clinical Professor of Psychiatry at Yale School of Medicine, where he previously led the Yale Clinical Neuroscience Research Unit and directed the Yale Obsessive-Compulsive Disorder Research Clinic. Dr. Coric earned his medical degree from Wake Forest University School of Medicine and a Bachelor of Science in Neurobiology and Physiology from the University of Connecticut.